Drug Details
| General Information of the Drug (ID: DR7740) | ||||
|---|---|---|---|---|
| Name |
BIBR1532
|
|||
| Synonyms |
BIBR 1532; 321674-73-1; BIBR1532; (E)-2-(3-(naphthalen-2-yl)but-2-enamido)benzoic acid; BIBR-1532; CHEMBL27323; 2-{[(2e)-3-(Naphthalen-2-Yl)but-2-Enoyl]amino}benzoic Acid; 2-[[(E)-3-naphthalen-2-ylbut-2-enoyl]amino]benzoic Acid; 2-(3-Naphthalen-2-yl-but-2-enoylamino)-benzoic acid; MLS006011127; SCHEMBL16964998; CHEBI:94985; DTXSID70432975; EX-A381; BIBR-1532/BIBR1532; IBR 1532; ABP000274; BDBM50126186; MFCD11112195; s1186; ZINC13488964; AKOS024457366; CCG-264852; CS-0902; SB19493; NCGC00242492-01; NCGC00242492-09; AC-26865; AS-56088; HY-17353; SMR004702907; SW219803-1; X7524; EC-000.2388; W-5477; 2-(3-(Naphthalen-2-yl)but-2-enamido)benzoic acid; BRD-K04623885-001-01-8; Q27455481; 2-[(e)-3-naphthalen-2-yl-but-2-enoylamino]-benzoic acid; 2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-butenyl]amino]benzoic acid; 2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoic acid; 2-[[(2E)-3-(2-Naphthalenyl)-1-oxo-2-butenyl1-yl]amino]benzoicacid; 2197129-84-1; 55C
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Lung cancer [ICD-11: 2C25] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C21H17NO3
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC(=CC(=O)NC1=CC=CC=C1C(=O)O)C2=CC3=CC=CC=C3C=C2
|
|||
| InChI |
1S/C21H17NO3/c1-14(16-11-10-15-6-2-3-7-17(15)13-16)12-20(23)22-19-9-5-4-8-18(19)21(24)25/h2-13H,1H3,(H,22,23)(H,24,25)/b14-12+
|
|||
| InChIKey |
PGFQXGLPJUCTOI-WYMLVPIESA-N
|
|||
| CAS Number |
CAS 321674-73-1
|
|||
| ChEBI ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Arsenic trioxide | Realgar and orpiment | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-xL | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MYC | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | TERT | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFC | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Induction | Cell cycle arrest in G1 phase | ||||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-231 | Breast cancer | Homo sapiens | ||||
| Experimental
Result(s) |
Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-KappaB signaling pathway. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Telomerase protein component 1 (TEP1) | Molecule Info | [1] | |
